Xortx Underscores Genetic Evidence for Xanthine Oxidase Targeting and Announces Board Update

Xortx Therapeutics has highlighted new peer-reviewed research linking genetic factors to increased xanthine oxidase (XO) activity, elevated uric acid levels, and the development of gout and kidney disease. The findings support the company’s strategy of inhibiting XO to treat gout, progressive kidney disorders, and related inflammatory conditions.

While hyperuricemia has traditionally been associated with diet and lifestyle, recent large-scale studies suggest genetics play a significant role. Research involving 2.6 million individuals identified more than 400 genetic factors associated with inflammatory mechanisms in gout, aligning with evidence of XO over-expression in humans. Additional studies link elevated XO activity to conditions including polycystic kidney disease, diabetes, sepsis, and kidney failure, reinforcing the potential for a precision medicine approach guided by genetic risk.

Xortx also announced the appointment of Krysta Davies Foss to its board, bringing more than 25 years of biotechnology strategy and commercialization experience. The company is advancing multiple clinical programmes targeting gout, kidney disease, and acute organ injury.

03-01-2026